{"protocolSection": {"identificationModule": {"nctId": "NCT02188784", "orgStudyIdInfo": {"id": "Pro00054061"}, "secondaryIdInfos": [{"id": "2U10HL084904", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/2U10HL084904"}], "organization": {"fullName": "Duke University", "class": "OTHER"}, "briefTitle": "Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure", "officialTitle": "Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure", "acronym": "IRONOUT"}, "statusModule": {"statusVerifiedDate": "2017-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-09-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-04-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-04-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-07-10", "studyFirstSubmitQcDate": "2014-07-11", "studyFirstPostDateStruct": {"date": "2014-07-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-12-30", "resultsFirstSubmitQcDate": "2017-04-05", "resultsFirstPostDateStruct": {"date": "2017-05-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-06-09", "lastUpdatePostDateStruct": {"date": "2017-07-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Adrian Hernandez", "investigatorTitle": "MD, MHS, FAHA: Associate Professor of Medicine;Director, Outcomes & Health Services Research", "investigatorAffiliation": "Duke University"}, "leadSponsor": {"name": "Adrian Hernandez", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine if oral iron (Fe) polysaccharide is superior to oral placebo in improving functional capacity as measured by change in peak VO2 (oxygen uptake) by CPET (Cardiopulmonary Exercise Testing) , of a broad population of patients with HFrEF (Heart Failure with Reduced Ejection Fraction) and Fe deficiency at 16 weeks.\n\nHypothesis: In a broad population of HFrEF patients with Fe deficiency, compared to oral placebo, therapy with oral Fe polysaccharide will be associated with improvement in functional capacity at 16 weeks as assessed by CPET.", "detailedDescription": "Therapeutic options to further improve functional capacity and symptoms in HF beyond neurohormonal antagonism are limited. Studies have demonstrated impaired oxidative capacity of skeletal muscle among HF patients, which may contribute to symptoms of breathlessness and persistent fatigue.\n\nIn addition to its role in erythropoiesis, iron (Fe) plays a critical role in skeletal muscle's oxygen (O2)-storage capacity (myoglobin) and systemic aerobic energy production. As Fe deficiency is common in patients with symptomatic HF, repletion of iron stores may improve submaximal exercise capacity among these patients beyond the effects on erythropoiesis.\n\nWhile intravenous Fe repletion in HF patients with mild Fe-deficiency (i.e. Ferritin \\<100 or Ferritin 100-299 with transferrin saturation \\<20%) with or without anemia global well-being and functional status, oral Fe repletion has not been studied. Furthermore, the efficacy of oral Fe to replete iron stores in a similar population and its impact on functional capacity, measured objectively by peak VO2, remains unknown."}, "conditionsModule": {"conditions": ["Chronic Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 225, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Polysaccharide iron complex 150 mg", "type": "ACTIVE_COMPARATOR", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks", "interventionNames": ["Drug: Polysaccharide Iron Complex 150 mg"]}, {"label": "Placebo (for Polysaccharide Iron Complex 150 mg)", "type": "PLACEBO_COMPARATOR", "description": "Oral placebo twice a day for 16 weeks", "interventionNames": ["Drug: Placebo (for Polysaccharide Iron Complex)"]}], "interventions": [{"type": "DRUG", "name": "Polysaccharide Iron Complex 150 mg", "description": "Oral Iron", "armGroupLabels": ["Polysaccharide iron complex 150 mg"], "otherNames": ["Feramax 150 mg"]}, {"type": "DRUG", "name": "Placebo (for Polysaccharide Iron Complex)", "description": "Sugar capsule designed to mimic Polysaccharide Iron Complex.", "armGroupLabels": ["Placebo (for Polysaccharide Iron Complex 150 mg)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Peak VO2 (ml/Min) (VO2 =Oxygen Consumption)", "description": "To determine if oral Fe (Iron) polysaccharide is superior to oral placebo in improving functional capacity as measured by change in peak VO2 by CPET (Cardiopulmonary Exercise Testing) , of a broad population of patients with HFrEF (Heart Failure with Reduced Ejection Fraction) and Fe deficiency at 16 weeks.", "timeFrame": "Baseline (BL) and Week 16"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Sub-maximal Exercise Capacity as Assessed by the 6 Minute Walk Test (6MWT)", "description": "To determine the impact of oral Fe repletion on Submaximal exercise capacity as measured by 6MWT", "timeFrame": "Measured at BL, week 8 and week 16"}, {"measure": "Change in Plasma NT-pro BNP", "description": "To determine the impact of oral Fe repletion on Plasma N-terminal pro-B-type natriuretic peptide (NT-pro BNP)", "timeFrame": "Measured at Baseline and Week 16"}, {"measure": "Change in Health Status: Kansas City Cardiomyopathy Questionnaire (KCCQ) - Clinical Summary Score", "description": "To determine the impact of oral Fe repletion on Health Status: KCCQ.\n\nKCCQ is a 23-item, self administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life for patients with congestive heart failure. It is a predictive tool that tracks how patients are doing if they have weakened heart muscle due to prior heart attacks, heart valve problems, viral infections, or other causes.\n\nThe KCCQs questions are used to calculate scores in ten domains. Physical Limitation, Symptom Stability, Frequency, Burden and Total Symptom. Social Limitation, Self-Efficacy, Quality of Life, and Clinical Summary. Overall summary: a combined measure of all the above.\n\nFor each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.", "timeFrame": "Measured at Baseline, Week 8 and Week 16"}, {"measure": "Change From Baseline in O2 Uptake Kinetics as Assessed by Mean Response Time From CPET", "description": "To determine the impact of oral Fe repletion on O2 Uptake Kinetics as measured by CPET", "timeFrame": "Measured at BL week 16"}, {"measure": "Change From Baseline in Ventilatory Efficiency Defined by Ve/VCO2", "description": "Change from baseline in Ventilatory Efficiency defined by Ve/VCO2 (carbon dioxide output) as measured by CPET", "timeFrame": "Measured at BL week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \\>18 years\n2. Previous clinical diagnosis of heart failure with current New York Heart Association (NYHA) Class II-IV symptoms LVEF\u22640.40 within 2 years prior to consent, and \u22653 months after a major change in cardiac status (i.e. CABG or CRT).\n3. Serum ferritin between 15-100 ng/ml or serum ferritin between 100-299 ng/ml with transferrin saturation \\<20%\n4. Hemoglobin 9.0-13.5 g/dL (males), 9-13.5 (females) at time of enrollment\n5. Stable evidence-based medical therapy for HF (including beta-blocker and ACE-inhibitor/ARB unless previously deemed intolerant, and diuretics as necessary) with \\</= 100% change in dose for 30 days prior to randomization\n\n   a. Changes in diuretic dose guided by a patient-directed flexible dosing program are considered stable medical therapy\n6. Willingness to provide informed consent\n\nExclusion Criteria:\n\n1. Presence of a neuromuscular, orthopedic or other non-cardiac condition that prevents the patient from exercise testing on a bicycle/treadmill ergometer and/or inability to achieve an RER \u2265 1.0 on screening/baseline CPET\n2. Severe renal dysfunction (eGFR\\< 20 ml/min/1.73m2)\n3. Severe liver disease (ALT or AST \\> 3x normal, alkaline phosphatase or bilirubin \\>2x normal)\n4. Gastrointestinal conditions known to impair Fe absorption (i.e. inflammatory bowel disease)\n5. Known active infection as defined by current use of oral or intravenous antimicrobial agents\n6. Documented active gastrointestinal bleeding\n7. Active malignancy other than non-melanoma skin cancers\n8. Anemia with known cause other than Fe deficiency or chronic disease\n9. Fe overload disorders (i.e. hemochromatosis or hemosiderosis)\n10. History of erythropoietin, IV or oral Fe therapy, or blood transfusion in previous 3 months.\n11. Current ventricular assist device\n12. Anticipated cardiac transplantation within the next 4 months\n13. Primary hypertrophic cardiomyopathy, infiltrative cardiomyopathy, acute myocarditis, constrictive pericarditis or tamponade\n14. Previous adverse reaction to study drug or other oral Fe preparation\n15. Known or anticipated pregnancy in the next 4 months", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Adrian Hernandez, MD,MHS,FAHA", "affiliation": "Duke University", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Emory University School of Medicine", "city": "Atlanta", "state": "Georgia", "zip": "30322", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "Johns Hopkins Hospital", "city": "Baltimore", "state": "Maryland", "zip": "21287", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Tufts Medical Center", "city": "Boston", "state": "Massachusetts", "zip": "02111", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Massachusetts General Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Mayo Clinic", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Saint Louis University Hospital", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Washington University School of Medicine", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Duke University Medical Center", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "University Hospitals-Case Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Metor Health System", "city": "Cleveland", "state": "Ohio", "zip": "44109", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Cleveland Clinic Foundation", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Lancaster General Hospital", "city": "Lancaster", "state": "Pennsylvania", "zip": "17603", "country": "United States", "geoPoint": {"lat": 40.03788, "lon": -76.30551}}, {"facility": "Hospital of the University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Thomas Jefferson University", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19107", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "University of Utah Hospitals and Clinics", "city": "Murray", "state": "Utah", "zip": "84107", "country": "United States", "geoPoint": {"lat": 40.66689, "lon": -111.88799}}, {"facility": "The University of Vermont - Fletcher Allen Health Care", "city": "Burlington", "state": "Vermont", "zip": "05401", "country": "United States", "geoPoint": {"lat": 44.47588, "lon": -73.21207}}]}, "referencesModule": {"references": [{"pmid": "28510680", "type": "DERIVED", "citation": "Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E; NHLBI Heart Failure Clinical Research Network. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017 May 16;317(19):1958-1966. doi: 10.1001/jama.2017.5427. Erratum In: JAMA. 2017 Jun 20;317(23 ):2453."}, {"pmid": "27140203", "type": "DERIVED", "citation": "Lewis GD, Semigran MJ, Givertz MM, Malhotra R, Anstrom KJ, Hernandez AF, Shah MR, Braunwald E. Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. Circ Heart Fail. 2016 May;9(5):e000345. doi: 10.1161/CIRCHEARTFAILURE.115.000345."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "After the study results have been published, site-specific participant data will be shared with sites upon request. Sites are expected to follow their specific institutional policies regarding sharing results with their participants."}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "FG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "111"}, {"groupId": "FG001", "numSubjects": "114"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "Patients completing the protocol excluding death, lost to follow-up and withdrawn consent.", "numSubjects": "102"}, {"groupId": "FG001", "comment": "Patients completing the protocol excluding death, lost to follow-up and withdrawn consent.", "numSubjects": "101"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All randomized patients", "groups": [{"id": "BG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "BG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "114"}, {"groupId": "BG002", "value": "225"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.8", "spread": "13.4"}, {"groupId": "BG001", "value": "51.6", "spread": "12.5"}, {"groupId": "BG002", "value": "61.7", "spread": "12.9"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "44"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "80"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "67"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "145"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "9"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "108"}, {"groupId": "BG001", "value": "107"}, {"groupId": "BG002", "value": "215"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "57"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "79"}, {"groupId": "BG001", "value": "85"}, {"groupId": "BG002", "value": "164"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "114"}, {"groupId": "BG002", "value": "225"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Peak VO2 (ml/Min) (VO2 =Oxygen Consumption)", "description": "To determine if oral Fe (Iron) polysaccharide is superior to oral placebo in improving functional capacity as measured by change in peak VO2 by CPET (Cardiopulmonary Exercise Testing) , of a broad population of patients with HFrEF (Heart Failure with Reduced Ejection Fraction) and Fe deficiency at 16 weeks.", "populationDescription": "All randomized patients with available change data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/min", "timeFrame": "Baseline (BL) and Week 16", "groups": [{"id": "OG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "OG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.04", "spread": "212.75"}, {"groupId": "OG001", "value": "3.90", "spread": "190.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4570", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "21.03", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-34.38", "ciUpperLimit": "76.43"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sub-maximal Exercise Capacity as Assessed by the 6 Minute Walk Test (6MWT)", "description": "To determine the impact of oral Fe repletion on Submaximal exercise capacity as measured by 6MWT", "populationDescription": "All randomized patients with available change data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "meters", "timeFrame": "Measured at BL, week 8 and week 16", "groups": [{"id": "OG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "OG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"title": "8 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "101"}, {"groupId": "OG001", "value": "97"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "12.65", "spread": "95.89"}, {"groupId": "OG001", "value": "16.63", "spread": "83.20"}]}]}, {"title": "16 weeks", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "97"}, {"groupId": "OG001", "value": "97"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.76", "spread": "62.29"}, {"groupId": "OG001", "value": "30.94", "spread": "77.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline to Week 8", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9487", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "-0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-24.12", "ciUpperLimit": "22.59"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from Baseline to Week 16", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1921", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "-12.67", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-31.71", "ciUpperLimit": "6.37"}]}, {"type": "SECONDARY", "title": "Change in Plasma NT-pro BNP", "description": "To determine the impact of oral Fe repletion on Plasma N-terminal pro-B-type natriuretic peptide (NT-pro BNP)", "populationDescription": "All randomized patients with available change data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Measured at Baseline and Week 16", "groups": [{"id": "OG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "OG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "98"}, {"groupId": "OG001", "value": "98"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "119.36", "spread": "1937.58"}, {"groupId": "OG001", "value": "-70.88", "spread": "1256.49"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4296", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "182.43", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-272.14", "ciUpperLimit": "637.0"}]}, {"type": "SECONDARY", "title": "Change in Health Status: Kansas City Cardiomyopathy Questionnaire (KCCQ) - Clinical Summary Score", "description": "To determine the impact of oral Fe repletion on Health Status: KCCQ.\n\nKCCQ is a 23-item, self administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life for patients with congestive heart failure. It is a predictive tool that tracks how patients are doing if they have weakened heart muscle due to prior heart attacks, heart valve problems, viral infections, or other causes.\n\nThe KCCQs questions are used to calculate scores in ten domains. Physical Limitation, Symptom Stability, Frequency, Burden and Total Symptom. Social Limitation, Self-Efficacy, Quality of Life, and Clinical Summary. Overall summary: a combined measure of all the above.\n\nFor each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.", "populationDescription": "All randomized patients with available change data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Measured at Baseline, Week 8 and Week 16", "groups": [{"id": "OG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "OG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "111"}, {"groupId": "OG001", "value": "114"}]}], "classes": [{"title": "Week 8", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "104"}, {"groupId": "OG001", "value": "103"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.25", "spread": "16.91"}, {"groupId": "OG001", "value": "0.58", "spread": "13.63"}]}]}, {"title": "Week 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "100"}, {"groupId": "OG001", "value": "100"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.42", "spread": "16.05"}, {"groupId": "OG001", "value": "4.11", "spread": "11.80"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline to week 8", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0722", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "3.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.33", "ciUpperLimit": "7.52"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Change from baseline to week 16", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6927", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "0.71", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.83", "ciUpperLimit": "4.24"}]}, {"type": "SECONDARY", "title": "Change From Baseline in O2 Uptake Kinetics as Assessed by Mean Response Time From CPET", "description": "To determine the impact of oral Fe repletion on O2 Uptake Kinetics as measured by CPET", "populationDescription": "All randomized patients with available change data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "seconds", "timeFrame": "Measured at BL week 16", "groups": [{"id": "OG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "OG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.63", "spread": "13.31"}, {"groupId": "OG001", "value": "-0.95", "spread": "13.29"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0643", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "3.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.21", "ciUpperLimit": "7.33"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Ventilatory Efficiency Defined by Ve/VCO2", "description": "Change from baseline in Ventilatory Efficiency defined by Ve/VCO2 (carbon dioxide output) as measured by CPET", "populationDescription": "All randomized patients with available change data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "VE/VCO2 Slope", "timeFrame": "Measured at BL week 16", "groups": [{"id": "OG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron"}, {"id": "OG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "95"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.48", "spread": "5.85"}, {"groupId": "OG001", "value": "-1.31", "spread": "8.85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4006", "statisticalMethod": "Regression, Linear", "paramType": "Mean Difference (Net)", "paramValue": "0.77", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.04", "ciUpperLimit": "2.58"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "timeFrame": "Randomization to Week 16", "eventGroups": [{"id": "EG000", "title": "Polysaccharide Iron Complex 150 mg", "description": "oral Fe polysaccharide 150mg twice daily for 16 weeks\n\nPolysaccharide Iron Complex 150 mg: Oral Iron", "seriousNumAffected": 11, "seriousNumAtRisk": 111, "otherNumAffected": 18, "otherNumAtRisk": 111}, {"id": "EG001", "title": "Placebo (for Polysaccharide Iron Complex 150 mg)", "description": "Oral placebo twice a day for 16 weeks\n\nPlacebo (for Polysaccharide Iron Complex): Sugar capsule designed to mimic Polysaccharide Iron Complex.", "seriousNumAffected": 9, "seriousNumAtRisk": 114, "otherNumAffected": 24, "otherNumAtRisk": 114}], "seriousEvents": [{"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Gastrointestinal Pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (10.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Rectal Haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Non-Cardiac Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Bronchitis Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Gastroenteritis Viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Streptococcal Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Vestibular Neuronitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Abdominal Injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Road Traffic Accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Liver Function Test Abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Norovirus Test Positive", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Hyperosmolar Hyperglycaemic State", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Musculoskeletal Chest Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Rhabdomyolysis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Skin Cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Alcohol Withdrawal Syndrome", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Hypertensive Crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Temporal Arteritis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}], "otherEvents": [{"term": "Abdominal Discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 114}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 7, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 114}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 114}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Non-Cardiac Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 114}]}, {"term": "Musculoskeletal Chest Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 114}]}, {"term": "Pain in Extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 114}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 19.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 111}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 114}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "To minimize the probability of inaccurate data in published materials, it is the policy of The Heart Failure Network (HFN) that all data and text considered for all papers, and all abstracts for presentation at scientific meetings, be submitted to the Publication \\& Presentation Subcommittee, the NHLBI Project Officer and the Coordinating Center for review and approval prior to presentation or publication."}, "pointOfContact": {"title": "Dr. Adrian Hernandez", "organization": "Duke Clinical Research Institute", "email": "adrian.hernandez@duke.edu", "phone": "919-668-7515"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007501", "term": "Iron"}], "ancestors": [{"id": "D000014131", "term": "Trace Elements"}, {"id": "D000018977", "term": "Micronutrients"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10533", "name": "Iron", "asFound": "Eko", "relevance": "HIGH"}, {"id": "M21009", "name": "Micronutrients", "relevance": "LOW"}, {"id": "M16885", "name": "Trace Elements", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Micro", "name": "Micronutrients"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}